In studies using OVX-induced osteoporotic ddY mice, Risedronate sodium was administered at 2.5mg/kg once daily for 28 days, with OVX controls for comparison. Reported trabecular bone volume was 35.71 ± 5.63%. Reported osteoclast cell number was 19.00 ± 2.93 N/epiphyseal. [1]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Trabecular Bone Volume in OVX-Induced Osteoporotic Mice
Animal study · OVX-induced osteoporotic ddY mice [1]
OVX-induced osteoporotic ddY mice received Risedronate sodium at 2.5mg/kg once daily for 28 days, with an OVX control for comparison. Trabecular bone volume was 35.71 ± 5.63%.
Conditions shared by the study groups
- Treatment course
- once daily for 28 days
- Risedronate sodium 2.5mg/kg
- Model: OVX-induced osteoporotic ddY mice
- Reported limits: Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Risedronate sodium; Compound label in the paper: Risedronate
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Effect of Nox inhibitor on OVX-induced osteoporosis (S44); Methods > Histomorphometrical analysis (S113); Figure 5 legend (S174); Table 1 legend (S192); Table 1 (T1.h2, T1.r3, T1.r4)
Trabecular bone volume (%): Trabecular bone volume (%); comparator: OVX — Table 1 legend (S192); Table 1 (T1.h2, T1.r4)
Risedronate sodium 2.5mg/kg · Methods > Histomorphometrical analysis (S113); Table 1 legend (S192); Table 1 (T1.h2, T1.r4)
Osteoclast Cell Number in OVX-Induced Osteoporotic Mice
Animal study · OVX-induced osteoporotic ddY mice [1]
OVX-induced osteoporotic ddY mice received Risedronate sodium at 2.5mg/kg once daily for 28 days, with an OVX control for comparison. Osteoclast cell number was 19.00 ± 2.93 N/epiphyseal.
Conditions shared by the study groups
- Treatment course
- once daily for 28 days
- Risedronate sodium 2.5mg/kg
- Model: OVX-induced osteoporotic ddY mice
- Reported limits: Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Risedronate sodium; Compound label in the paper: Risedronate
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Effect of Nox inhibitor on OVX-induced osteoporosis (S44); Methods > Histomorphometrical analysis (S113); Figure 5 legend (S174); Table 2 legend (S194); Table 2 (T2.h2, T2.r3, T2.r4)
Osteoclast cell number (N/epiphyseal): Osteoclast cell number (N/epiphyseal); comparator: OVX — Table 2 legend (S194); Table 2 (T2.h2, T2.r4)
Risedronate sodium 2.5mg/kg · Methods > Histomorphometrical analysis (S113); Table 2 legend (S194); Table 2 (T2.h2, T2.r4)